Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard Mackey

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Journal of Biopharmaceutical Statistics|April 23, 2009
Some notable properties of the standard oncology Phase I designGregory J Hather, Howard Mackey
Biometrical Journal. Biometrische Zeitschrift|February 15, 2021
Power and sample size for random coefficient regression models in randomized experiments with monotone missing dataNan Hu, Howard Mackey, Ronald Thomas
Contemporary Clinical Trials|May 8, 2013
An industry statistician's perspective on PHC drug developmentJane Fridlyand, Ru-Fang Yeh, Howard Mackey, et al.
European Journal of Dermatology : EJD|June 25, 2015
The incidence of metastatic basal cell carcinoma (mBCC) in Denmark, 1997-2010Mary Nguyen-Nielsen, Lisa Wang, Lars Pedersen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 21, 2007
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancerStephen A Cannistra, Ursula A Matulonis, Richard T Penson, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 30, 2018
The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical <i>PSEN1</i> E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohortPierre N Tariot, Francisco Lopera, Jessica B Langbaum, et al.
JAMA Neurology|September 19, 2022
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled TrialsSusanne Ostrowitzki, Tobias Bittner, Kaycee M Sink, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 18, 2020
Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal-Dominant Alzheimer's Disease Colombia TrialSilvia Rios-Romenets, Francisco Lopera, Kaycee M Sink, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Journal of Biopharmaceutical Statistics|April 23, 2009
Some notable properties of the standard oncology Phase I designGregory J Hather, Howard Mackey
Biometrical Journal. Biometrische Zeitschrift|February 15, 2021
Power and sample size for random coefficient regression models in randomized experiments with monotone missing dataNan Hu, Howard Mackey, Ronald Thomas
Contemporary Clinical Trials|May 8, 2013
An industry statistician's perspective on PHC drug developmentJane Fridlyand, Ru-Fang Yeh, Howard Mackey, et al.
European Journal of Dermatology : EJD|June 25, 2015
The incidence of metastatic basal cell carcinoma (mBCC) in Denmark, 1997-2010Mary Nguyen-Nielsen, Lisa Wang, Lars Pedersen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 21, 2007
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancerStephen A Cannistra, Ursula A Matulonis, Richard T Penson, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 30, 2018
The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical <i>PSEN1</i> E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohortPierre N Tariot, Francisco Lopera, Jessica B Langbaum, et al.
JAMA Neurology|September 19, 2022
Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled TrialsSusanne Ostrowitzki, Tobias Bittner, Kaycee M Sink, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 18, 2020
Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal-Dominant Alzheimer's Disease Colombia TrialSilvia Rios-Romenets, Francisco Lopera, Kaycee M Sink, et al.
Pageof 1